Zevra Therapeutics, Inc. Research and Development Expense (Excluding Acquired in Process Cost)
Zevra Therapeutics, Inc. (ZVRA) reported Research and Development Expense (Excluding Acquired in Process Cost) of $4.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2026-08-05
- Zevra Therapeutics, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2026-06-30 was $4.49M, a 30.67% increase year-over-year.
- Zevra Therapeutics, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2026-03-31 was $4.39M, a 34.81% increase year-over-year.
- Zevra Therapeutics, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2025-12-31 was $2.62M, a 68.63% decline year-over-year.
- Zevra Therapeutics, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2025-09-30 was $3.43M, a 68.64% decline year-over-year.
- Zevra Therapeutics, Inc. research and development expense (excluding acquired in process cost) for fiscal 2025 was $12.74M, a 69.73% decline from fiscal 2024.
- Zevra Therapeutics, Inc. research and development expense (excluding acquired in process cost) for fiscal 2024 was $42.09M, a 5.75% increase from fiscal 2023.
- Zevra Therapeutics, Inc. research and development expense (excluding acquired in process cost) for fiscal 2023 was $39.81M, a 101.01% increase from fiscal 2022.
- Zevra Therapeutics, Inc. research and development expense (excluding acquired in process cost) for fiscal 2022 was $19.80M, a 94.89% increase from fiscal 2021.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 3 month as first filed | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month as first filed | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month as first filed | Research and Development Expense (Excluding Acquired in Process Cost) 12 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.49M 10-Q · filed 2026-08-05 | $8.88M 10-Q · filed 2026-08-05 | $11.50M derived: sum of 3 quarters · filed 2026-08-05 | $14.93M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $4.39M 10-Q · filed 2026-05-06 | $7.01M derived: sum of 2 quarters · filed 2026-05-06 | $10.44M derived: sum of 3 quarters · filed 2026-05-06 | $13.88M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $6.05M derived: sum of 2 quarters · filed 2026-03-09 | $9.48M derived: sum of 3 quarters · filed 2026-08-05 | $12.74M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $3.43M 10-Q · filed 2025-11-05 | $6.87M derived: sum of 2 quarters · filed 2026-08-05 | $10.12M 10-Q · filed 2025-11-05 | $18.48M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $3.43M 10-Q · filed 2026-08-05 | $6.69M 10-Q · filed 2026-08-05 | $15.04M derived: sum of 3 quarters · filed 2026-08-05 | $25.99M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $3.26M 10-Q · filed 2026-05-06 | $11.61M derived: sum of 2 quarters · filed 2026-05-06 | $22.55M derived: sum of 3 quarters · filed 2026-05-06 | $33.08M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $8.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $19.30M derived: sum of 2 quarters · filed 2026-03-09 | $29.82M derived: sum of 3 quarters · filed 2026-03-09 | $42.09M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $10.95M 10-Q · filed 2025-11-05 | $21.47M derived: sum of 2 quarters · filed 2025-11-05 | $33.74M 10-Q · filed 2025-11-05 | $45.16M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $10.52M 10-Q · filed 2025-08-12 | $22.80M 10-Q · filed 2025-08-12 | $34.22M derived: sum of 3 quarters · filed 2025-08-12 | $46.52M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $12.28M 10-Q · filed 2025-05-13 | $23.70M derived: sum of 2 quarters · filed 2025-05-13 | $35.99M derived: sum of 3 quarters · filed 2025-05-13 | $43.43M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $11.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $23.72M derived: sum of 2 quarters · filed 2025-03-12 | $31.15M derived: sum of 3 quarters · filed 2025-03-12 | $39.81M 10-K · filed 2025-03-12 | ||||
| 2023-09-30 | $12.30M 10-Q · filed 2024-11-13 | $19.73M derived: sum of 2 quarters · filed 2024-11-13 | $28.39M 10-Q · filed 2024-11-13 | $28.57M 10-Q · filed 2023-11-07 | $34.93M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $7.43M 10-Q · filed 2024-08-14 | $16.09M 10-Q · filed 2024-08-14 | $16.28M 10-Q · filed 2023-08-14 | $22.63M derived: sum of 3 quarters · filed 2024-08-14 | $28.01M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $8.65M 10-Q · filed 2024-05-09 | $8.84M 10-Q · filed 2023-05-15 | $15.20M derived: sum of 2 quarters · filed 2024-05-09 | $20.58M derived: sum of 3 quarters · filed 2024-05-09 | $25.38M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $11.93M derived: sum of 2 quarters · filed 2024-04-01 | $16.72M derived: sum of 3 quarters · filed 2024-04-01 | $19.80M 10-K · filed 2024-04-01 | $19.61M 10-K · filed 2023-03-07 | |||
| 2022-09-30 | $5.38M 10-Q · filed 2023-11-07 | $10.18M derived: sum of 2 quarters · filed 2023-11-07 | $13.26M 10-Q · filed 2023-11-07 | $16.07M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $4.79M 10-Q · filed 2023-08-14 | $7.88M 10-Q · filed 2023-08-14 | $10.69M derived: sum of 3 quarters · filed 2023-08-14 | $12.93M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $3.08M 10-Q · filed 2023-05-15 | $5.89M derived: sum of 2 quarters · filed 2023-05-15 | $8.13M derived: sum of 3 quarters · filed 2023-05-15 | $10.98M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $5.05M derived: sum of 2 quarters · filed 2023-03-07 | $7.90M derived: sum of 3 quarters · filed 2023-03-07 | $10.16M 10-K · filed 2023-03-07 | ||||
| 2021-09-30 | $2.24M 10-Q · filed 2022-11-10 | $5.09M derived: sum of 2 quarters · filed 2022-11-10 | $7.35M 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | $2.85M 10-Q · filed 2022-08-12 | $5.11M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |